Market highlights for next week: XM and Sirius reporting
Posted Feb 23rd 2007 4:05PM by Eric Buscemi
Filed under: Earnings Reports, Conventions and Conferences, Annual Meetings, XM Satellite Radio (XMSR), Sirius Satellite Radio (SIRI), Novartis AG ADS (NVS)
Monday February 26
- XM Satellite Radio Holdings Inc (NASDAQ: XMSR) to report Q4 earnings; conference call at 10am. Analysts will review XM's overall subscribers, new subscribers, retention rates, average monthly fees, pricing plans, new broadcast content agreements, marketing strategy, operating costs, sector position, and margins. Equally significant, Wall Street will also pay very close attention to management's operational posture moving forward, in light of its proposed merger agreement with Sirius Satellite Radio Inc (NASDAQ: SIRI).
Tuesday February 27
- Sirius Satellite Radio to report Q4 earnings; conference call at 8am. The concerns for Sirius mirror the previously mentioned concerns for XM.
Wednesday February 28
- PDUFA Date for Novartis AG ADS's (NYSE: NVS) Galvus, an innovative oral therapy for people with type 2 diabetes.
Thursday March 1
- Echostar Communications Corporation (NASDAQ: DISH) to report Q4 earnings; conference call at 12pm. Analysts will focus on Echostar's success at adding value to its offerings, amid intensifying competition from digital cable and communications companies offering TV services.
- PDUFA date for New River Pharmaceuticals Inc (NASDAQ: NRPH) and Shire plc ADS's (NASDAQ: SHPGY) Vyvanse, for the treatment of Attention Deficit Hyperactivity Disorder [ADHD].
- PDUFA date for Merck Serono SA ADS's (NYSE: SRA) Serostim, a treatment for AIDs wasting.
Friday March 2
- THQ Inc (NASDAQ: THQI) to hold analyst meeting in San Fransisco, CA.
Tags: analyst meeting, AnalystMeeting, dish, earnings, echostar, galvus, look ahead, LookAhead, merck serono, MerckSerono, new river, NewRiver, novartis, nrph, nvs, pdufa, preview, report, serostim, shire, shpgy, siri, sirius, sra, thq, thqi, vyvanse, xm, xmsr
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
